Recombinant protein vaccines against the asexual blood-stages of Plasmodium falciparum

Human Vaccines

Volumn 6, Issue 1, 2010, Pages

  Anders, Robin F ^a   Adda, Christopher G ^a   Foley, Michael ^a   Norton, Raymond S ^b  

^a LA TROBE UNIVERSITY   (Australia)

^b WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

Blood stages; Malaria; Plasmodium; Recombinant protein; Vaccine

Indexed keywords

AGATOLIMOD; ALUMINUM HYDROXIDE; APICAL MEMBRANE ANTIGEN 1; AS 02; AS 02 A; AS 02A; CIRCUMSPOROZOITE PROTEIN; ERYTHROCYTE BINDING ANTIGEN; GLUTAMATE RICH PROTEIN; GMZ 2; IMMUNOLOGICAL ADJUVANT; MALARIA VACCINE; MEROZOITE SURFACE ANTIGEN 3; MEROZOITE SURFACE PROTEIN 1; MEROZOITE SURFACE PROTEIN 2; MONTANIDE; MONTANIDE ISA 720; PARASITE ANTIGEN; PEPTIDE VACCINE; PF 07 0128; PF 10 0344; PF 10 0345; PF 11 0344; PFB 0300 C; PFB 0340 C; PFI 1475 W; RECOMBINANT PROTEIN; RECOMBINANT VACCINE; RING INFECTED ERYTHROCYTE SURFACE ANTIGEN; SERINE REPEAT ANTIGEN 5; UNCLASSIFIED DRUG; WATER OIL CREAM; APICAL MEMBRANE ANTIGEN I, PLASMODIUM; MEMBRANE PROTEIN; MEROZOITE SURFACE PROTEIN 2, PLASMODIUM; PROTOZOAL PROTEIN; PROTOZOON ANTIBODY;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ANTIGEN STRUCTURE; ANTIGENICITY; CLINICAL TRIAL; DRUG FORMULATION; DRUG STRUCTURE; HUMAN; MALARIA FALCIPARUM; NONHUMAN; PARASITE DEVELOPMENT; PLASMODIUM FALCIPARUM; REVIEW; ESCHERICHIA COLI; GENE EXPRESSION; GENETICS; IMMUNOLOGY;

ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; CLINICAL TRIALS AS TOPIC; ESCHERICHIA COLI; GENE EXPRESSION; HUMANS; MALARIA VACCINES; MALARIA, FALCIPARUM; MEMBRANE PROTEINS; PLASMODIUM FALCIPARUM; PROTOZOAN PROTEINS; VACCINES, SYNTHETIC;

EID: 85046915432     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.6.1.10712     Document Type: Review

References (165)

1. Trager W, Jensen JB. Human malaria parasites in continuous culture. Science 1976; 193:673-5.
2. www.malariavaccineroadmap.net. Malaria vaccine technology roadmap. 2005.
3. Kemp DJ, Coppel RL, Cowman AF, Saint RB, Brown GV, Anders RF. Expression of Plasmodium falciparum blood-stage antigens in Escherichia coli: detection with antibodies from immune humans. Proc Natl Acad Sci USA 1983; 80:3787-91.
4. Gray JC, Corran PH, Mangia E, Gaunt MW, Li Q, Tetteh KK, et al. Profiling the antibody immune response against blood stage malaria vaccine candidates. Clin Chem 2007; 53:1244-53.
5. Osier FH, Fegan G, Polley SD, Murungi L, Verra F, Tetteh KK, et al. Breadth and magnitude of antibody responses to multiple Plasmodium falciparum merozoite antigens are associated with protection from clinical malaria. Infect Immun 2008; 76:2240-8.
6. Holder AA, Freeman RR. Biosynthesis and processing of a Plasmodium falciparum schizont antigen recognized by immune serum and a monoclonal antibody. J Exp Med 1982; 156:1528-38.
7. Deans JA, Alderson T, Thomas AW, Mitchell GH, Lennox ES, Cohen S. Rat monoclonal antibodies which inhibit the in vitro multiplication of Plasmodium knowlesi. Clin Exp Immunol 1982; 49:297-309.
8. Stanley HA, Howard RF, Reese RT. Recognition of a Mr 56 K glycoprotein on the surface of Plasmodium falciparum merozoites by mouse monoclonal antibodies. J Immunol 1985; 134:3439-44.
9. Smythe JA, Coppel RL, Brown GV, Ramasamy R, Kemp DJ, Anders RF. Identification of two integral membrane proteins of Plasmodium falciparum. Proc Natl Acad Sci USA 1988; 85:5195-9.
10. Crewther PE, Bianco AE, Brown GV, Coppel RL, Stahl HD, Kemp DJ, et al. Affinity purification of human antibodies directed against cloned antigens of Plasmodium falciparum. J Immunol Methods 1986; 86:257-64.
11. Knapp B, Hundt E, Enders B, Kupper HA. Protection of Aotus monkeys from malaria infection by immunization with recombinant hybrid proteins. Infect Immun 1992; 60:2397-401.
12. Collins WE, Anders RF, Pappaioanou M, Campbell GH, Brown GV, Kemp DJ, et al. Immunization of Aotus monkeys with recombinant proteins of an erythrocyte surface antigen of Plasmodium falciparum. Nature 1986; 323:259-62.
13. Holder AA, Freeman RR. Immunization against blood-stage rodent malaria using purified parasite antigens. Nature 1981; 294:361-4.
14. Deans JA, Thomas AW, Alderson T, Cohen S. Biosynthesis of a putative protective Plasmodium knowlesi merozoite antigen. Mol Biochem Parasitol 1984; 11:189-204.
15. Fenton B, Clark JT, Wilson CF, McBride JS, Walliker D. Polymorphism of a 35-48 kDa Plasmodium falciparum merozoite surface antigen. Mol Biochem Parasitol 1989; 34:79-86.
16. Camus D, Hadley TJ. A Plasmodium falciparum antigen that binds to host erythrocytes and merozoites. Science 1985; 230:553-6.
17. Sim BK, Orlandi PA, Haynes JD, Klotz FW, Carter JM, Camus D, et al. Primary structure of the 175 K Plasmodium falciparum erythrocyte binding antigen and identification of a peptide which elicits antibodies that inhibit malaria merozoite invasion. J Cell Biol 1990; 111:1877-84.
18. Borre MB, Dziegiel M, Hogh B, Petersen E, Rieneck K, Riley E, et al. Primary structure and localization of a conserved immunogenic Plasmodium falciparum glutamate rich protein (GLURP) expressed in both the preerythrocytic and erythrocytic stages of the vertebrate life cycle. Mol Biochem Parasitol 1991; 49:119-31.
19. Oeuvray C, Bouharoun-Tayoun H, Gras-Masse H, Bottius E, Kaidoh T, Aikawa M, et al. Merozoite surface protein-3: a malaria protein inducing antibodies that promote Plasmodium falciparum killing by cooperation with blood monocytes. Blood 1994; 84:1594-602.
20. McColl DJ, Silva A, Foley M, Kun JF, Favaloro JM, Thompson JK, et al. Molecular variation in a novel polymorphic antigen associated with Plasmodium falciparum merozoites. Mol Biochem Parasitol 1994; 68:53-67.
21. Li WB, Bzik DJ, Horii T, Inselburg J. Structure and expression of the Plasmodium falciparum SERA gene. Mol Biochem Parasitol 1989; 33:13-25.
22. Hodder AN, Malby RL, Clarke OB, Fairlie WD, Colman PM, Crabb BS, et al. Structural insights into the protease-like antigen Plasmodium falciparum SERA5 and its noncanonical active-site serine. J Mol Biol 2009; 392:154-65.
23. Genton B, Reed ZH. Asexual blood-stage malaria vaccine development: facing the challenges. Curr Opin Infect Dis 2007; 20:467-75.
24. Gardner MJ, Hall N, Fung E, White O, Berriman M, Hyman RW, et al. Genome sequence of the human malaria parasite Plasmodium falciparum. Nature 2002; 419:498-511.
25. Sanders PR, Gilson PR, Cantin GT, Greenbaum DC, Nebl T, Carucci DJ, et al. Distinct protein classes including novel merozoite surface antigens in Raftlike membranes of Plasmodium falciparum. J Biol Chem 2005; 280:40169-76.
26. Regis DP, Dobano C, Quinones-Olson P, Liang X, Graber NL, Stefaniak ME, et al. Transcriptionally active PCR for antigen identification and vaccine development: in vitro genome-wide screening and in vivo immunogenicity. Mol Biochem Parasitol 2008; 158:32-45.
27. Villard V, Agak GW, Frank G, Jafarshad A, Servis C, Nebie I, et al. Rapid identification of malaria vaccine candidates based on alpha-helical coiled coil protein motif. PLoS One 2007; 2:645.
28. Kulangara C, Kajava AV, Corradin G, Felger I. Sequence conservation in Plasmodium falciparum alpha-helical coiled coil domains proposed for vaccine development. PLoS One 2009; 4:5419.
29. Mu J, Awadalla P, Duan J, McGee KM, Keebler J, Seydel K, et al. Genome-wide variation and identification of vaccine targets in the Plasmodium falciparum genome. Nat Genet 2007; 39:126-30.
30. Tetteh KK, Stewart LB, Ochola LI, Amambua-Ngwa A, Thomas AW, Marsh K, et al. Prospective identification of malaria parasite genes under balancing selection. PLoS One 2009; 4:5568.
31. Holder AA. The carboxy-terminus of merozoite surface protein 1: structure, specific antibodies and immunity to malaria. Parasitology 2009; 136:1445-56.
32. Genton B, Betuela I, Felger I, Al-Yaman F, Anders RF, Saul A, et al. A recombinant blood-stage malaria vaccine reduces Plasmodium falciparum density and exerts selective pressure on parasite populations in a phase 1-2b trial in Papua New Guinea. J Infect Dis 2002; 185:820-7.
33. Blackman MJ, Heidrich HG, Donachie S, McBride JS, Holder AA. A single fragment of a malaria merozoite surface protein remains on the parasite during red cell invasion and is the target of invasioninhibiting antibodies. J Exp Med 1990; 172:379-82.
34. Blackman MJ, Holder AA. Secondary processing of the Plasmodium falciparum merozoite surface protein-1 (MSP1) by a calcium-dependent membranebound serine protease: shedding of MSP133 as a noncovalently associated complex with other fragments of the MSP1. Mol Biochem Parasitol 1992; 50:307-15.
35. Keitel WA, Kester KE, Atmar RL, White AC, Bond NH, Holland CA, et al. Phase I trial of two recombinant vaccines containing the 19 kd carboxy terminal fragment of Plasmodium falciparum merozoite surface protein 1 (msp-1(19)) and T helper epitopes of tetanus toxoid. Vaccine 1999; 18:531-9.
36. Ockenhouse CF, Angov E, Kester KE, Diggs C, Soisson L, Cummings JF, et al. Phase I safety and immunogenicity trial of FMP1/AS02A, a Plasmodium falciparum MSP-1 asexual blood stage vaccine. Vaccine 2006; 24:3009-17.
37. Stoute JA, Gombe J, Withers MR, Siangla J, McKinney D, Onyango M, et al. Phase 1 randomized double-blind safety and immunogenicity trial of Plasmodium falciparum malaria merozoite surface protein FMP1 vaccine, adjuvanted with AS02A, in adults in western Kenya. Vaccine 2007; 25:176-84.
38. Thera MA, Doumbo OK, Coulibaly D, Diallo DA, Sagara I, Dicko A, et al. Safety and allele-specific immunogenicity of a malaria vaccine in Malian adults: results of a phase I randomized trial. PLoS Clin Trials 2006; 1:34.
39. Withers MR, McKinney D, Ogutu BR, Waitumbi JN, Milman JB, Apollo OJ, et al. Safety and reactogenicity of an MSP-1 malaria vaccine candidate: a randomized phase Ib dose-escalation trial in Kenyan children. PLoS Clin Trials 2006; 1:32.
40. Ogutu BR, Apollo OJ, McKinney D, Okoth W, Siangla J, Dubovsky F, et al. Blood stage malaria vaccine eliciting high antigen-specific antibody concentrations confers no protection to young children in western Kenya. PLoS One 2009; 4:4708.
41. Malkin E, Long CA, Stowers AW, Zou L, Singh S, MacDonald NJ, et al. Phase 1 study of two merozoite surface protein 1 (MSP1(42)) vaccines for Plasmodium falciparum malaria. PLoS Clin Trials 2007; 2:12.
42. Crompton PD, Mircetic M, Weiss G, Baughman A, Huang CY, Topham DJ, et al. The TLR9 ligand CpG promotes the acquisition of Plasmodium falciparumspecific memory B cells in malaria-naive individuals. J Immunol 2009; 182:3318-26.
43. www.ClinicalTrials.gov. Phase I study of the safety and immunogenicity of BSAM-2/Alhydrogel (Registered Trademark) + CpG 7909, an asexual blood stage vaccine for Plasmodium falciparum malaria in adults in the US and Mali. 2009; NCT00889616.
44. Saul A, Lawrence G, Allworth A, Elliott S, Anderson K, Rzepczyk C, et al. A human phase 1 vaccine clinical trial of the Plasmodium falciparum malaria vaccine candidate apical membrane antigen 1 in Montanide ISA 720 adjuvant. Vaccine 2005; 23:3076-83.
45. Dutta S, Lalitha PV, Ware LA, Barbosa A, Moch JK, Vassell MA, et al. Purification, characterization and immunogenicity of the refolded ectodomain of the Plasmodium falciparum apical membrane antigen 1 expressed in Escherichia coli. Infect Immun 2002; 70:3101-10.
46. Polhemus ME, Magill AJ, Cummings JF, Kester KE, Ockenhouse CF, Lanar DE, et al. Phase I dose escalation safety and immunogenicity trial of Plasmodium falciparum apical membrane protein (AMA-1) FMP2.1, adjuvanted with AS02A, in malaria-naive adults at the Walter Reed Army Institute of Research. Vaccine 2007; 25:4203-12.
47. Thera MA, Doumbo OK, Coulibaly D, Diallo DA, Kone AK, Guindo AB, et al. Safety and immunogenicity of an AMA-1 malaria vaccine in Malian adults: results of a phase 1 randomized controlled trial. PLoS One 2008; 3:1465.
48. Lyke KE, Daou M, Diarra I, Kone A, Kouriba B, Thera MA, et al. Cell-mediated immunity elicited by the blood stage malaria vaccine apical membrane antigen 1 in Malian adults: results of a Phase I randomized trial. Vaccine 2009; 27:2171-6.
49. Spring MD, Cummings JF, Ockenhouse CF, Dutta S, Reidler R, Angov E, et al. Phase 1/2a study of the malaria vaccine candidate apical membrane antigen-1 (AMA-1) administered in adjuvant system AS01B or AS02A. PLoS One 2009; 4:5254.
50. th Multilateral Initiative on Malaria Pan-African Malaria Conference. Nairobi, Kenya 2009; 210.
51. Malkin EM, Diemert DJ, McArthur JH, Perreault JR, Miles AP, Giersing BK, et al. Phase 1 clinical trial of apical membrane antigen 1: an asexual blood-stage vaccine for Plasmodium falciparum malaria. Infect Immun 2005; 73:3677-85.
52. Dicko A, Diemert DJ, Sagara I, Sogoba M, Niambele MB, Assadou MH, et al. Impact of a Plasmodium falciparum AMA1 vaccine on antibody responses in adult Malians. PLoS One 2007; 2:1045.
53. Dicko A, Sagara I, Ellis RD, Miura K, Guindo O, Kamate B, et al. Phase 1 study of a combination AMA1 blood stage malaria vaccine in Malian children. PLoS One 2008; 3:1563.
54. Sagara I, Dicko A, Ellis RD, Fay MP, Diawara SI, Assadou MH, et al. A randomized controlled phase 2 trial of the blood stage AMA1-C1/Alhydrogel malaria vaccine in children in Mali. Vaccine 2009; 27:3090-8.
55. Mullen GE, Ellis RD, Miura K, Malkin E, Nolan C, Hay M, et al. Phase 1 trial of AMA1-C1/Alhydrogel plus CPG 7909: an asexual blood-stage vaccine for Plasmodium falciparum malaria. PLoS One 2008; 3:2940.
56. Ellis RD, Mullen GE, Pierce M, Martin LB, Miura K, Fay MP, et al. A Phase 1 study of the blood-stage malaria vaccine candidate AMA1-C1/Alhydrogel with CPG 7909, using two different formulations and dosing intervals. Vaccine 2009; 27:4104-9.
57. Sagara I, Ellis RD, Dicko A, Niambele MB, Kamate B, Guindo O, et al. A randomized and controlled Phase 1 study of the safety and immunogenicity of the AMA1-C1/Alhydrogel((R)) + CPG 7909 vaccine for Plasmodium falciparum malaria in semi-immune Malian adults. Vaccine 2009.
58. www.ClinicalTrials.gov. Malaria vaccine for children in Mali. 2009; NCT00740090.
59. www.ClinicalTrials.gov. A study to assess safety, immunogenicity and parasite growth inhibition of an asexual blood stage vaccine for P. falciparum malaria. 2009; NCT00984763.
60. www.ClinicalTrials.gov. Phase 1 study of the safety, reactogenicity and immunogenicity of AMA-C1/ISA 720: Blood stage vaccine for Plasmodium falciparum 2009; NCT00487916.
61. Faber BW, Remarque EJ, Kocken CH, Cheront P, Cingolani D, Xhonneux F, et al. Production, quality control, stability and pharmacotoxicity of cGMPproduced Plasmodium falciparum AMA1 FVO strain ectodomain expressed in Pichia pastoris. Vaccine 2008; 26:6143-50.
62. Roestenberg M, Remarque E, de Jonge E, Hermsen R, Blythman H, Leroy O, et al. Safety and immunogenicity of a recombinant Plasmodium falciparum AMA1 malaria vaccine adjuvanted with Alhydrogel, Montanide ISA 720 or AS02. PLoS One 2008; 3:3960.
63. Sturchler D, Berger R, Rudin C, Just M, Saul A, Rzepczyk C, et al. Safety, immunogenicity and pilot efficacy of Plasmodium falciparum sporozoite and asexual blood-stage combination vaccine in Swiss adults. Am J Trop Med Hyg 1995; 53:423-31.
64. Saul A, Lawrence G, Smillie A, Rzepczyk CM, Reed C, Taylor D, et al. Human phase I vaccine trials of 3 recombinant asexual stage malaria antigens with Montanide ISA 720 adjuvant. Vaccine 1999; 17:3145-59.
65. Genton B, Al-Yaman F, Anders R, Saul A, Brown G, Pye D, et al. Safety and immunogenicity of a threecomponent blood-stage malaria vaccine in adults living in an endemic area of Papua New Guinea. Vaccine 2000; 18:2504-11.
66. Lawrence G, Cheng QQ, Reed C, Taylor D, Stowers A, Cloonan N, et al. Effect of vaccination with 3 recombinant asexual-stage malaria antigens on initial growth rates of Plasmodium falciparum in nonimmune volunteers. Vaccine 2000; 18:1925-31.
67. Genton B, Al-Yaman F, Betuela I, Anders RF, Saul A, Baea K, et al. Safety and immunogenicity of a threecomponent blood-stage malaria vaccine (MSP1, MSP2, RESA) against Plasmodium falciparum in Papua New Guinean children. Vaccine 2003; 22:30-41.
68. www.anzctr.org.au. Safety and tolerability trial of a randomised, placebo-controlled MSP2-C1/ISA 720 malaria vaccine in healthy volunteers. 2007; ACTN12607000552482.
69. Pan W, Huang D, Zhang Q, Qu L, Zhang D, Zhang X, et al. Fusion of two malaria vaccine candidate antigens enhances product yield, immunogenicity and antibody-mediated inhibition of parasite growth in vitro. J Immunol 2004; 172:6167-74.
70. Malkin E, Hu J, Li Z, Chen Z, Bi X, Reed Z, et al. A phase 1 trial of PfCP2.9: an AMA1/MSP1 chimeric recombinant protein vaccine for Plasmodium falciparum malaria. Vaccine 2008; 26:6864-73.
71. Hu J, Chen Z, Gu J, Wan M, Shen Q, Kieny MP, et al. Safety and immunogenicity of a malaria vaccine, Plasmodium falciparum AMA-1/MSP-1 chimeric protein formulated in montanide ISA 720 in healthy adults. PLoS One 2008; 3:1952.
72. Theisen M, Soe S, Brunstedt K, Follmann F, Bredmose L, Israelsen H, et al. A Plasmodium falciparum GLURP-MSP3 chimeric protein; expression in Lactococcus lactis, immunogenicity and induction of biologically active antibodies. Vaccine 2004; 22:1188-98.
73. Singh S, Soe S, Mejia JP, Roussilhon C, Theisen M, Corradin G, et al. Identification of a conserved region of Plasmodium falciparum MSP3 targeted by biologically active antibodies to improve vaccine design. J Infect Dis 2004; 190:1010-8.
74. Esen M, Kremsner PG, Schleucher R, Gassler M, Imoukhuede EB, Imbault N, et al. Safety and immunogenicity of GMZ2-a MSP3-GLURP fusion protein malaria vaccine candidate. Vaccine 2009; 27:6862-8.
75. www.ClinicalTrials.gov. Safety of recombinant hybrid GMZ2 (GLURP + MSP3) blood stage malaria vaccine. 2008; NCT00424944.
76. www.ClinicalTrials.gov. Safety and immunogenicity of 30 and 100 ug of GMZ2 in Gabonese children aged 1-5 years. 2008; NCT00703066.
77. Hermsen CC, Verhage DF, Telgt DS, Teelen K, Bousema JT, Roestenberg M, et al. Glutamate-rich protein (GLURP) induces antibodies that inhibit in vitro growth of Plasmodium falciparum in a phase 1 malaria vaccine trial. Vaccine 2007; 25:2930-40.
78. Audran R, Cachat M, Lurati F, Soe S, Leroy O, Corradin G, et al. Phase I malaria vaccine trial with a long synthetic peptide derived from the merozoite surface protein 3 antigen. Infect Immun 2005; 73:8017-26.
79. Sirima SB, Nebie I, Ouedraogo A, Tiono AB, Konate AT, Gansane A, et al. Safety and immunogenicity of the Plasmodium falciparum merozoite surface protein-3 long synthetic peptide (MSP3-LSP) malaria vaccine in healthy, semi-immune adult males in Burkina Faso, West Africa. Vaccine 2007; 25:2723-32.
80. www.ClinicalTrials.gov. Safety and immunogenicity og EBA-175 RII-NG malaria vaccine administered intramuscularly. 2009; NCT00347555.
81. Horii T. Malaria vaccine. Nippon Rinsho 2008; 66:1990-8.
82. Bisser S, Ouwe-Missi-Oukem-Boyer ON, Toure FS, Taoufiq Z, Bouteille B, Buguet A, et al. Harbouring in the brain: A focus on immune evasion mechanisms and their deleterious effects in malaria and human African trypanosomiasis. Int J Parasitol 2006; 36:529-40.
83. Pouniotis DS, Proudfoot O, Minigo G, Hanley JL, Plebanski M. Malaria parasite interactions with the human host. J Postgrad Med 2004; 50:30-4.
84. Hodder AN, Crewther PE, Anders RF. Specificity of the protective antibody response to apical membrane antigen 1. Infect Immun 2001; 69:3286-94.
85. Miura K, Zhou H, Muratova OV, Orcutt AC, Giersing B, Miller LH, et al. In immunization with Plasmodium falciparum apical membrane antigen 1, the specificity of antibodies depends on the species immunized. Infect Immun 2007; 75:5827-36.
86. Lyon JA, Angov E, Fay MP, Sullivan JS, Girourd AS, Robinson SJ, et al. Protection induced by Plasmodium falciparum MSP1(42) is strain-specific, antigen and adjuvant dependent, and correlates with antibody responses. PLoS One 2008; 3:2830.
87. Reed ZH, Kieny MP, Engers H, Friede M, Chang S, Longacre S, et al. Comparison of immunogenicity of five MSP1-based malaria vaccine candidate antigens in rabbits. Vaccine 2009; 27:1651-60.
88. Lazarou M, Guevara Patino JA, Jennings RM, McIntosh RS, Shi J, Howell S, et al. Inhibition of erythrocyte invasion and Plasmodium falciparum Merozoite Surface Protein 1 processing by human IgG1 and IgG3 antibodies. Infect Immun 2009.
89. Persson KE, McCallum FJ, Reiling L, Lister NA, Stubbs J, Cowman AF, et al. Variation in use of erythrocyte invasion pathways by Plasmodium falciparum mediates evasion of human inhibitory antibodies. J Clin Invest 2008; 118:342-51.
90. Kennedy MC, Wang J, Zhang Y, Miles AP, Chitsaz F, Saul A, et al. In vitro studies with recombinant Plasmodium falciparum apical membrane antigen 1 (AMA1): production and activity of an AMA1 vaccine and generation of a multiallelic response. Infect Immun 2002; 70:6948-60.
91. Kocken CH, Withers-Martinez C, Dubbeld MA, van der Wel A, Hackett F, Valderrama A, et al. High-level expression of the malaria blood-stage vaccine candidate Plasmodium falciparum apical membrane antigen 1 and induction of antibodies that inhibit erythrocyte invasion. Infect Immun 2002; 70:4471-6.
92. Dutta S, Sullivan JS, Grady KK, Haynes JD, Komisar J, Batchelor AH, et al. High antibody titer against apical membrane antigen-1 is required to protect against malaria in the Aotus model. PLoS One 2009; 4:e8138.
93. Bouharoun-Tayoun H, Oeuvray C, Lunel F, Druilhe P. Mechanisms underlying the monocyte-mediated antibody-dependent killing of Plasmodium falciparum asexual blood stages. J Exp Med 1995; 182:409-18.
94. Theisen M, Soe S, Jessing SG, Okkels LM, Danielsen S, Oeuvray C, et al. Identification of a major B-cell epitope of the Plasmodium falciparum glutamate-rich protein (GLURP), targeted by human antibodies mediating parasite killing. Vaccine 2000; 19:204-12.
95. Druilhe P, Khusmith S. Epidemiological correlation between levels of antibodies promoting merozoite phagocytosis of Plasmodium falciparum and malariaimmune status. Infect Immun 1987; 55:888-91.
96. Taylor RR, Allen SJ, Greenwood BM, Riley EM. IgG3 antibodies to Plasmodium falciparum merozoite surface protein 2 (MSP2): increasing prevalence with age and association with clinical immunity to malaria. Am J Trop Med Hyg 1998; 58:406-13.
97. Oeuvray C, Theisen M, Rogier C, Trape JF, Jepsen S, Druilhe P. Cytophilic immunoglobulin responses to Plasmodium falciparum glutamate-rich protein are correlated with protection against clinical malaria in Dielmo, Senegal. Infect Immun 2000; 68:2617-20.
98. Courtin D, Oesterholt M, Huismans H, Kusi K, Milet J, Badaut C, et al. The quantity and quality of African children's IgG responses to merozoite surface antigens reflect protection against Plasmodium falciparum malaria. PLoS One 2009; 4:7590.
99. Ndungu FM, Bull PC, Ross A, Lowe BS, Kabiru E, Marsh K. Naturally acquired immunoglobulin (Ig) G subclass antibodies to crude asexual Plasmodium falciparum lysates: evidence for association with protection for IgG1 and disease for IgG2. Parasite Immunol 2002; 24:77-82.
100. Henderson KA, Streltsov VA, Coley AM, Dolezal O, Hudson PJ, Batchelor AH, et al. Structure of an IgNAR-AMA1 complex: targeting a conserved hydrophobic cleft broadens malarial strain recognition. Structure 2007; 15:1452-66.
101. Coley AM, Gupta A, Murphy VJ, Bai T, Kim H, Foley M, et al. Structure of the malaria antigen AMA1 in complex with a growth-inhibitory antibody. PLoS Pathog 2007; 3:1308-19.
102. Collins CR, Withers-Martinez C, Bentley GA, Batchelor AH, Thomas AW, Blackman MJ. Fine mapping of an epitope recognized by an invasioninhibitory monoclonal antibody on the malaria vaccine candidate apical membrane antigen 1. J Biol Chem 2007; 282:7431-41.
103. Cavanagh DR, Remarque EJ, Sauerwein RW, Hermsen CC, Luty AJ. Influenza virosomes: a flu jab for malaria? Trends Parasitol 2008; 24:382-5.
104. Okitsu SL, Mueller MS, Amacker M, Vogel D, Westerfeld N, Robinson JA, et al. Preclinical profiling of the immunogenicity of a two-component subunit malaria vaccine candidate based on virosome technology. Hum Vaccin 2008; 4:106-14.
105. Thompson FM, Porter DW, Okitsu SL, Westerfeld N, Vogel D, Todryk S, et al. Evidence of blood stage efficacy with a virosomal malaria vaccine in a phase IIa clinical trial. PLoS One 2008; 3:1493.
106. Hodder AN, Crewther PE, Matthew ML, Reid GE, Moritz RL, Simpson RJ, et al. The disulfide bond structure of Plasmodium apical membrane antigen-1. J Biol Chem 1996; 271:29446-52.
107. Singh S, Kennedy MC, Long CA, Saul AJ, Miller LH, Stowers AW. Biochemical and immunological characterization of bacterially expressed and refolded Plasmodium falciparum 42-kilodalton C-terminal merozoite surface protein 1. Infect Immun 2003; 71:6766-74.
108. Peterson MG, Marshall VM, Smythe JA, Crewther PE, Lew A, Silva A, et al. Integral membrane protein located in the apical complex of Plasmodium falciparum. Mol Cell Biol 1989; 9:3151-4.
109. Howell SA, Withers-Martinez C, Kocken CH, Thomas AW, Blackman MJ. Proteolytic processing and primary structure of Plasmodium falciparum apical membrane antigen-1. J Biol Chem 2001; 276:31311-20.
110. Triglia T, Healer J, Caruana SR, Hodder AN, Anders RF, Crabb BS, et al. Apical membrane antigen 1 plays a central role in erythrocyte invasion by Plasmodium species. Mol Microbiol 2000; 38:706-18.
111. Silvie O, Franetich JF, Charrin S, Mueller MS, Siau A, Bodescot M, et al. A role for apical membrane antigen 1 during invasion of hepatocytes by Plasmodium falciparum sporozoites. J Biol Chem 2004; 279:9490-6.
112. Healer J, Crawford S, Ralph S, McFadden G, Cowman AF. Independent translocation of two micronemal proteins in developing Plasmodium falciparum merozoites. Infect Immun 2002; 70:5751-8.
113. Bannister LH, Hopkins JM, Dluzewski AR, Margos G, Williams IT, Blackman MJ, et al. Plasmodium falciparum apical membrane antigen 1 (PfAMA-1) is translocated within micronemes along subpellicular microtubules during merozoite development. J Cell Sci 2003; 116:3825-34.
114. Narum DL, Thomas AW. Differential localization of full-length and processed forms of PF83/AMA-1 an apical membrane antigen of Plasmodium falciparum merozoites. Mol Biochem Parasitol 1994; 67:59-68.
115. Collins CR, Withers-Martinez C, Hackett F, Blackman MJ. An inhibitory antibody blocks interactions between components of the malarial invasion machinery. PLoS Pathog 2009; 5:1000273.
116. Collins WE, Pye D, Crewther PE, Vandenberg KL, Galland GG, Sulzer AJ, et al. Protective immunity induced in squirrel monkeys with recombinant apical membrane antigen-1 of Plasmodium fragile. Am J Trop Med Hyg 1994; 51:711-9.
117. Stowers AW, Kennedy MC, Keegan BP, Saul A, Long CA, Miller LH. Vaccination of monkeys with recombinant Plasmodium falciparum apical membrane antigen 1 confers protection against blood-stage malaria. Infect Immun 2002; 70:6961-7.
118. Dutta S, Sullivan JS, Grady KK, Haynes JD, Komisar J, Batchelor A, et al. High antibody titer against apical membrane antigen-1 is required to protect against malaria in the Aotus model. PLoS One 2009; in press.
119. Anders RF, Crewther PE, Edwards S, Margetts M, Matthew ML, Pollock B, et al. Immunisation with recombinant AMA-1 protects mice against infection with Plasmodium chabaudi. Vaccine 1998; 16:240-7.
120. Crewther PE, Matthew ML, Flegg RH, Anders RF. Protective immune responses to apical membrane antigen 1 of Plasmodium chabaudi involve recognition of strain-specific epitopes. Infect Immun 1996; 64:3310-7.
121. Burns JM Jr, Flaherty PR, Nanavati P, Weidanz WP. Protection against Plasmodium chabaudi malaria induced by immunization with apical membrane antigen 1 and merozoite surface protein 1 in the absence of gamma interferon or interleukin-4. Infect Immun 2004; 72:5605-12.
122. Burns JM Jr, Flaherty PR, Romero MM, Weidanz WP. Immunization against Plasmodium chabaudi malaria using combined formulations of apical membrane antigen-1 and merozoite surface protein-1. Vaccine 2003; 21:1843-52.
123. Narum DL, Ogun SA, Thomas AW, Holder AA. Immunization with parasite-derived apical membrane antigen 1 or passive immunization with a specific monoclonal antibody protects BALB/c mice against lethal Plasmodium yoelii yoelii YM bloodstage infection. Infect Immun 2000; 68:2899-906.
124. Deans JA, Knight AM, Jean WC, Waters AP, Cohen S, Mitchell GH. Vaccination trials in rhesus monkeys with a minor, invariant, Plasmodium knowlesi 66 kD merozoite antigen. Parasite Immunol 1988; 10:535-52.
125. + T cells acting independently of antibody contribute to protective immunity to Plasmodium chabaudi infection after apical membrane antigen 1 immunization. J Immunol 2000; 165:389-96.
126. Nair M, Hinds MG, Coley AM, Hodder AN, Foley M, Anders RF, et al. Structure of domain III of the blood-stage malaria vaccine candidate, Plasmodium falciparum apical membrane antigen 1 (AMA1). J Mol Biol 2002; 322:741-53.
127. Pizarro JC, Vulliez-Le Normand B, Chesne-Seck ML, Collins CR, Withers-Martinez C, Hackett F, et al. Crystal structure of the malaria vaccine candidate apical membrane antigen 1. Science 2005; 308:408-11.
128. Bai T, Becker M, Gupta A, Strike P, Murphy VJ, Anders RF, et al. Structure of AMA1 from Plasmodium falciparum reveals a clustering of polymorphisms that surround a conserved hydrophobic pocket. Proc Natl Acad Sci USA 2005; 102:12736-41.
129. Coley AM, Campanale NV, Casey JL, Hodder AN, Crewther PE, Anders RF, et al. Rapid and precise epitope mapping of monoclonal antibodies against Plasmodium falciparum AMA1 by combined phage display of fragments and random peptides. Protein Eng 2001; 14:691-8.
130. Coley AM, Parisi K, Masciantonio R, Hoeck J, Casey JL, Murphy VJ, et al. The most polymorphic residue on Plasmodium falciparum apical membrane antigen 1 determines binding of an invasion-inhibitory antibody. Infect Immun 2006; 74:2628-36.
131. Dutta S, Lee SY, Batchelor AH, Lanar DE. Structural basis of antigenic escape of a malaria vaccine candidate. Proc Natl Acad Sci USA 2007; 104:12488-93.
132. Gilson PR, Nebl T, Vukcevic D, Moritz RL, Sargeant T, Speed TP, et al. Identification and stoichiometry of glycosylphosphatidylinositol-anchored membrane proteins of the human malaria parasite Plasmodium falciparum. Mol Cell Proteomics 2006; 5:1286-99.
133. Gerold P, Schofield L, Blackman MJ, Holder AA, Schwarz RT. Structural analysis of the glycosyl-phosphatidylinositol membrane anchor of the merozoite surface proteins-1 and -2 of Plasmodium falciparum. Mol Biochem Parasitol 1996; 75:131-43.
134. Dubbeld MA, Kocken CH, Thomas AW. Merozoite surface protein 2 of Plasmodium reichenowi is a unique mosaic of Plasmodium falciparum allelic forms and species-specific elements. Mol Biochem Parasitol 1998; 92:187-92.
135. Cowman AF, Baldi DL, Duraisingh M, Healer J, Mills KE, O'Donnell RA, et al. Functional analysis of Plasmodium falciparum merozoite antigens: implications for erythrocyte invasion and vaccine development. Philos Trans R Soc Lond B Biol Sci 2002; 357:25-33.
136. Sanders PR, Kats LM, Drew DR, O'Donnell RA, O'Neill M, Maier AG, et al. A set of glycosylphosphatidyl inositol-anchored membrane proteins of Plasmodium falciparum is refractory to genetic deletion. Infect Immun 2006; 74:4330-8.
137. Franks S, Baton L, Tetteh K, Tongren E, Dewin D, Akanmori BD, et al. Genetic diversity and antigenic polymorphism in Plasmodium falciparum: extensive serological cross-reactivity between allelic variants of merozoite surface protein 2. Infect Immun 2003; 71:3485-95.
138. Smythe JA, Peterson MG, Coppel RL, Saul AJ, Kemp DJ, Anders RF. Structural diversity in the 45-kilodalton merozoite surface antigen of Plasmodium falciparum. Mol Biochem Parasitol 1990; 39:227-34.
139. Felger I, Irion A, Steiger S, Beck HP. Genotypes of merozoite surface protein 2 of Plasmodium falciparum in Tanzania. Trans R Soc Trop Med Hyg 1999; 93:3-9.
140. Irion A, Beck HP, Felger I. New repeat unit and hot spot of recombination in FC27-type alleles of the gene coding for Plasmodium falciparum merozoite surface protein 2. Mol Biochem Parasitol 1997; 90:367-70.
141. Smythe JA, Coppel RL, Day KP, Martin RK, Oduola AM, Kemp DJ, et al. Structural diversity in the Plasmodium falciparum merozoite surface antigen 2. Proc Natl Acad Sci USA 1991; 88:1751-5.
142. Fenton B, Clark JT, Khan CM, Robinson JV, Walliker D, Ridley R, et al. Structural and antigenic polymorphism of the 35- to 48-kilodalton merozoite surface antigen (MSA-2) of the malaria parasite Plasmodium falciparum. Mol Cell Biol 1991; 11:963-71.
143. Ramasamy R. Characterisation of a novel merozoite membrane antigen of the human malaria parasite Plasmodium falciparum. Immunol Cell Biol 1987; 1987:419-23.
144. Epping RJ, Goldstone SD, Ingram LT, Upcroft JA, Ramasamy R, Cooper JA, et al. An epitope recognised by inhibitory monoclonal antibodies that react with a 51 kilodalton merozoite surface antigen in Plasmodium falciparum. Mol Biochem Parasitol 1988; 28:1-10.
145. Clark JT, Donachie S, Anand R, Wilson CF, Heidrich HG, McBride JS. 46-53 kilodalton glycoprotein from the surface of Plasmodium falciparum merozoites. Mol Biochem Parasitol 1989; 32:15-24.
146. Flueck C, Frank G, Smith T, Jafarshad A, Nebie I, Sirima SB, et al. Evaluation of two long synthetic merozoite surface protein 2 peptides as malaria vaccine candidates. Vaccine 2009; 27:2653-61.
147. Taylor RR, Smith DB, Robinson VJ, McBride JS, Riley EM. Human antibody response to Plasmodium falciparum merozoite surface protein 2 is serogroup specific and predominantly of the immunoglobulin G3 subclass. Infect Immun 1995; 63:4382-8.
148. Rzepczyk CM, Hale K, Woodroffe N, Bobogare A, Csurhes P, Ishii A, et al.
149. al-Yaman F, Genton B, Anders RF, Falk M, Triglia T, Lewis D, et al. Relationship between humoral response to Plasmodium falciparum merozoite surface antigen-2 and malaria morbidity in a highly endemic area of Papua New Guinea. Am J Trop Med Hyg 1994; 51:593-602.
150. Metzger WG, Okenu DM, Cavanagh DR, Robinson JV, Bojang KA, Weiss HA, et al. Serum IgG3 to the Plasmodium falciparum merozoite surface protein 2 is strongly associated with a reduced prospective risk of malaria. Parasite Immunol 2003; 25:307-12.
151. Polley SD, Conway DJ, Cavanagh DR, McBride JS, Lowe BS, Williams TN, et al. High levels of serum antibodies to merozoite surface protein 2 of Plasmodium falciparum are associated with reduced risk of clinical malaria in coastal Kenya. Vaccine 2006; 24:4233-46.
152. Adda CG, Murphy VJ, Sunde M, Waddington LJ, Schloegel J, Talbo GH, et al. Plasmodium falciparum merozoite surface protein 2 is unstructured and forms amyloid-like fibrils. Mol Biochem Parasitol 2009; 166:159-71.
153. Zhang X, Perugini MA, Yao S, Adda CG, Murphy VJ, Low A, et al. Solution conformation, backbone dynamics and lipid interactions of the intrinsically unstructured malaria surface protein MSP2. J Mol Biol 2008; 379:105-21.
154. Feng ZP, Zhang X, Han P, Arora N, Anders RF, Norton RS. Abundance of intrinsically unstructured proteins in P. falciparum and other apicomplexan parasite proteomes. Mol Biochem Parasitol 2006; 150:256-67.
155. LaCount DJ, Vignali M, Chettier R, Phansalkar A, Bell R, Hesselberth JR, et al. A protein interaction network of the malaria parasite Plasmodium falciparum. Nature 2005; 438:103-7.
156. Yang X, Adda CG, Keizer DW, Murphy VJ, Rizkalla MM, Perugini MA, et al. A partially structured region of a largely unstructured protein, Plasmodium falciparum merozoite surface protein 2 (MSP2), forms amyloid-like fibrils. J Pept Sci 2007; 13:839-48.
157. Low A, Chandrashekaran IR, Adda CG, Yao S, Sabo JK, Zhang X, et al. Merozoite surface protein 2 of Plasmodium falciparum: expression, structure, dynamics and fibril formation of the conserved N-terminal domain. Biopolymers 2007; 87:12-22.
158. Uversky VN. Intrinsically Disordered Proteins and Their Environment: Effects of Strong Denaturants, Temperature, pH, Counter Ions, Membranes, Binding Partners, Osmolytes and Macromolecular Crowding. Protein J 2009; In press.
159. Dyson HJ, Wright PE. Intrinsically unstructured proteins and their functions. Nat Rev Mol Cell Biol 2005; 6:197-208.
160. Irion A. Molecular diversity and immunological properties of the Plasmodium falciparum merozoite surface protein 2 (MSP2). PhD Thesis 2000.
161. Takala SL, Plowe CV. Genetic diversity and malaria vaccine design, testing and efficacy: preventing and overcoming 'vaccine resistant malaria'. Parasite Immunol 2009; 31:560-73.
162. Barclay VC, Chan BH, Anders RF, Read AF. Mixed allele malaria vaccines: host protection and withinhost selection. Vaccine 2008; 26:6099-107.
163. Duan J, Mu J, Thera MA, Joy D, Kosakovsky Pond SL, Diemert D, et al. Population structure of the genes encoding the polymorphic Plasmodium falciparum apical membrane antigen 1: implications for vaccine design. Proc Natl Acad Sci USA 2008; 105:7857-62.
164. Remarque EJ, Faber BW, Kocken CH, Thomas AW. A diversity-covering approach to immunization with Plasmodium falciparum apical membrane antigen 1 induces broader allelic recognition and growth inhibition responses in rabbits. Infect Immun 2008; 76:2660-70.
165. Faber BW, Remarque EJ, Morgan WD, Kocken CH, Holder AA, Thomas AW. Malaria vaccine-related benefits of a single protein comprising Plasmodium falciparum apical membrane antigen 1 domains I and II fused to a modified form of the 19-kilodalton C-terminal fragment of merozoite surface protein 1. Infect Immun 2007; 75:5947-55.